Table 1.
Patient demographics and baseline characteristics
| Patient characteristics | Pneumonia group (n=179)a | Non-pneumonia group (n=50)b | P-valuec |
|---|---|---|---|
| Mean age (SE), years | 64.0 (0.69) | 63.8 (1.34) | 0.880 |
| Male/female, n (%) | 107 (60)/72 (40) | 26 (52)/24 (48) | ND |
| Mean BMI (SE), kg/m2 | 24.9 (0.47) | 27.5 (0.74) | 0.008 |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 15 (8) | 13 (26) | |
| Other | 164 (92) | 37 (74) | ND |
| Geometric mean post-bronchodilator FEV1 (% CV), L | 1.11 (37.47) | 1.18 (32.62) | 0.245 |
| Mean post-bronchodilator FEV1/FVC ratio (SE), % | 42.3 (0.83) | 47.6 (1.66) | 0.003 |
| Percent predicted post-bronchodilator FEV1 (SE), % | 41.7 (0.99) | 45.2 (1.72) | 0.096 |
Notes: Statistically significant P-values (P≤0.05) are shown in bold.
a
Original treatment assignment for the 179 patients in the pneumonia group was: FF 50 µg/VI 25 g, n=48; FF 100 µg/VI 25 µg, n=51; FF 200 µg/VI 25 µg n=53; VI 25 µg, n=27.
b
Original treatment assignment for the 50 patients in the non-pneumonia group was: FF 50 µg/VI 25 µg, n=21; FF 100 µg/VI 25 µg, n=8; FF 200 µg/VI 25 µg n=11; VI 25 µg, n=10.
c
Student’s t-test.
Abbreviations: BMI, body mass index; CV, coefficient of variation; FEV1, forced expiratory volume in 1 second; FF, fluticasone furoate; FVC, forced vital capacity; ND, not determined; SE, standard error; VI, vilanterol.